Biomarkers for precision therapy and prevention of type 2 diabetes

10 March 2020 | 2—5PM | Malmö

By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.

Three years into the project, the RHAPSODY team is eager to share its achievements with patient and healthcare communities in the Öresund region and welcomes all to a half-day symposium on March 10, 2020.


Scania University Hospital
Jan Waldenströms gata 1
21428 Malmö, Sweden

Other information

- Free of charge
- Registration mandatory
Stacks Image p6845_n47
Stacks Image p6845_n398
Stacks Image p6845_n51
Stacks Image p6845_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking ( under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.